CTI receives EU conditional marketing authorization for Pixuvri to treat non-Hodgkin B-cell lymphomas

CellTherapeutics today announced that it has received conditional marketing authorization from the European Commission for Pixuvri® (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixuvri is the first approved treatment in the European Union in this patient setting.

The decision allows CTI to market Pixuvri in the 27 Member States of the EU. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri in the EU in 2H2012

A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorization for Pixuvri, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.

As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.

Source:

CellTherapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Duke-NUS team develops test to monitor engineered T cells in cancer treatment